Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre

In KEYNOTE-042 pembrolizumab improved overall survival (OS) versus chemotherapy in patients with advanced/metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥1% (mOS 16.4m v 12.1m, HR 0.79). Our aim was to audit real-world evidence for pembrolizumab and associations with the lung immune prognostic index (LIPI). LIPI utilises baseline lactate dehydrogenase (LDH>ULN) and derived neutrophil lymphocyte ratio (dNLR≥3) to categorise risk of immunotherapy resistance (good=0 factors; intermediate=1; poor=2).